- Home
- MIST vs RLAY Comparison
MIST vs RLAY Comparison
Compare MIST & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | RLAY |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.3M | 1.3B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MIST | RLAY |
|---|---|---|
| Price | $1.69 | $10.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $8.50 | ★ $15.67 |
| AVG Volume (30 Days) | 1.2M | ★ 2.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.80 | 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $396.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $0.63 | $1.78 |
| 52 Week High | $3.06 | $11.49 |
Technical Indicators
Market Signals| Indicator | MIST | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 59.61 |
| Support Level | $1.60 | $9.06 |
| Resistance Level | $1.79 | $11.43 |
| Average True Range (ATR) | 0.08 | 0.78 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 71.15 | 53.28 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).